Lifestyle Program Tests Exercise and Diet for Fatty Liver and Heart Risk
Tests exercise and diet changes in adults with fatty liver disease or gallstones.
Plain-language title generated from the registry record
Registry title: Prevention of NAFLD and CVD Through Lifestyle Intervention
Key facts
- Where
- Molina, ChileSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 60 years old?
Source: NCT05618626, who can take part
Where in Chile
- Centro MAUCO+Molina, ChileTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pontificia Universidad Catolica de Chile
- Trial code
- NCT05618626
- Record updated
- 19 November 2024
- Original description
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.Read full original descriptionShow less
Cardiovascular Diseases (CVD) and Nonalcoholic Fatty Liver Diseases (NAFLD) Among Gallstone and Cholecystectomy Patients and the Impact of a Novel Diet and Muscle Training Program
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.
Inclusion: With and without gallstones disease; With various degrees of NAFLD (none too severe).
Exclusion: Use of medications that alter muscle mass (e.g., corticosteroids); Use of hepatotoxic drugs; History of hepatitis B or C; Any significant comorbidity or physical limitation to undergo resistance exercise program.